Epidemiology of SARS-CoV-2 in Low-income Countries.
低收入国家 SARS-CoV-2 的流行病学。
基本信息
- 批准号:10188735
- 负责人:
- 金额:$ 63.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAcquired Immunodeficiency SyndromeAddressAdultAfricanAntibodiesAreaArrhythmiaAutopsyCOVID-19COVID-19 pandemicCardiacCaringCellular PhoneCessation of lifeChronic lung diseaseClinicalClinical TrialsCohort AnalysisCollaborationsCommunicationCommunitiesConduct Clinical TrialsCountryDataDevelopmentDiseaseEchocardiographyElectrocardiogramEmergency SituationEnrollmentEpidemicEpidemiologyFunctional disorderFundingFutureGeographyGoalsHIVHIV InfectionsHIV/TBHaitiHaitianHealthHeart DiseasesHeart InjuriesHome environmentHospital RecordsHypertensionImmunoglobulin GIncidenceIncomeInfectionInfrastructureIntervention TrialLeftLeft Ventricular FunctionLow incomeMotionMyocardial IschemiaMyocarditisNational Institute of Allergy and Infectious DiseaseNatural HistoryOutcomeParticipantPatientsPopulationPositioning AttributePrevalencePreventionPreventive InterventionProceduresProtocols documentationPulmonary HypertensionPulmonary TuberculosisReport (document)ReportingResearchResearch InfrastructureRiskRisk FactorsSeminalSerologic testsSeveritiesSurvivorsSymptomsTanzaniaTelephoneTelephone InterviewsTroponinUnited States National Institutes of HealthUniversitiesVentricularViral Respiratory Tract InfectionVirus DiseasesVisitWorld Health Organizationcohortfallsfollow-upheart functionimprovedinfection ratelow income countrymortalitypandemic diseasepublic health interventionsymptomatology
项目摘要
The COVID-19 pandemic has now spread from high- and middle-income countries to low-income countries,
including Haiti and Tanzania. The natural history of COVID-19 is unknown in low-income countries. We
propose to study a combined cohort of 3,054 adults in Haiti and Tanzania to determine the attack rate of
SARS-CoV-2 infection and severe COVID-19, to examine interactions with HIV infection, pulmonary
tuberculosis, and hypertension in populations of African descent, and to determine long term cardiac
complications of COVID-19. Cornell University has collaborated with the Groupe Haitien d’Etude du Sarcome
de Kaposi et des Infections Opportunistes (GHESKIO) in Haiti for 38 years and for 15 years with the Mwanza
Intervention Trials Unit (MITU) in Tanzania. The proposed emergency supplement leverages these
collaborations and four established NIH-supported cohorts, which have already been enrolled, to address
NIAID priority areas. The specific aims are:
1.To determine the incidence proportion of SARS-CoV-2 infection and the attack rate and risk factors
for severe COVID-19, in well characterized cohorts of 3,054 adults from low-income communities in
Haiti and Tanzania. Starting May 1, 2020 we will conduct monthly telephone interviews with the 3,054
participants who are in active follow-up to record symptoms of COVID-19 during the pandemic. Participants will
also be encouraged to telephone us if they develop new symptoms. We have cell phone numbers for all
cohort participants and have established procedures for telephone communication. We will also review hospital
records, perform verbal autopsies, and grade severity of COVID-19. We have banked sera from all participants
collected in 2016-2019. In September-November 2020 and again in March-May 2021, we will collect follow-up
sera and perform serologic testing for the presence of anti-SARS-CoV-2 IgG antibodies. We will determine the
odds for development of severe COVID-19 in participants who had HIV, TB, and hypertension.
2. To determine the cardiac complications of SARS-CoV-2 infection in 1,909 adults with known baseline
cardiac function. In 1,909 patients who previously had baseline EKGs and echocardiograms (2016-2019), we
will repeat cardiac echo and EKG in 2021 to quantify the odds for development of incident left ventricular
systolic dysfunction in those who did and did not become SARS-CoV-2 infected. LV function will be quantified
by global longitudinal strain. We will also determine incidence of right ventricular systolic dysfunction,
pulmonary hypertension and segmental wall motion abnormalities by echocardiogram, and new Q-waves and
other abnormalities on EKG.
Defining viral infection rates and natural history in low-income countries will be critical for future prevention
interventions. Determining risk for people with HIV, TB, and hypertension will improve their care and
prevention. Understanding cardiac sequelae of SARS-CoV-2 will improve care for COVID-19 survivors.
COVID-19大流行现已从高收入和中等收入国家蔓延至低收入国家,
包括海地和坦桑尼亚,COVID-19 的自然史在低收入国家尚不清楚。
建议对海地和坦桑尼亚的 3,054 名成年人进行联合队列研究,以确定以下疾病的发病率:
SARS-CoV-2 感染和严重的 COVID-19,以检查与 HIV 感染、肺部感染的相互作用
非洲裔人群中的结核病和高血压,并确定长期心脏病
康奈尔大学与 Groupe Haitien d’Etude du Sarcome 合作。
de Kaposi et des Infections Opportunistes (GHESKIO) 在海地工作了 38 年,并在 Mwanza 工作了 15 年
坦桑尼亚的干预试验单位(MITU)拟议的紧急补充利用了这些。
合作和四个已建立的 NIH 支持的队列,这些队列已经注册,以解决
NIAID 的优先领域是:
1.确定SARS-CoV-2感染的发病比例以及发病率和危险因素
针对严重的 COVID-19,在来自低收入社区的 3,054 名成年人组成的特征明确的队列中
从 2020 年 5 月 1 日起,我们将每月对海地和坦桑尼亚的 3,054 人进行电话采访。
在大流行期间积极跟踪记录 COVID-19 症状的参与者 参与者将。
如果他们出现新症状,也请给我们打电话,我们有所有人的手机号码。
我们还将审查医院。
我们已储存所有参与者的血清,进行口头尸检并评估其严重程度。
2016年至2019年收集,2021年3月至5月再次收集,我们将收集后续信息。
血清并进行血清学检测以确定是否存在抗 SARS-CoV-2 IgG 抗体。
患有艾滋病毒、结核病和高血压的参与者出现严重 COVID-19 的几率。
2. 确定 1,909 名基线已知的成年人感染 SARS-CoV-2 后的心脏并发症
在 1,909 名之前进行过基线心电图和超声心动图检查(2016-2019 年)的患者中,我们进行了心脏功能检查。
将在 2021 年重复心脏超声和心电图,以量化发生左心室事件的几率
感染和未感染 SARS-CoV-2 的患者的收缩功能障碍将被量化。
我们还将确定右心室收缩功能障碍的发生率,
超声心动图显示肺动脉高压和节段性室壁运动异常,以及新的 Q 波和
心电图的其他异常。
确定低收入国家的病毒感染率和自然史对于未来的预防至关重要
确定艾滋病毒、结核病和高血压患者的风险将改善他们的护理和治疗。
了解 SARS-CoV-2 的心脏后遗症将改善对 COVID-19 幸存者的护理。
项目成果
期刊论文数量(69)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of C-2 substitution on the stability of non-traditional cephalosporins in mouse plasma.
C-2取代对非传统头孢菌素在小鼠血浆中稳定性的影响。
- DOI:10.1038/s41429-019-0167-y
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Zimmerman,Matthew;McDonald,StaceyL;Ho-Liang,Hsin-Pin;Porubsky,Patrick;Nguyen,Quyen;Pharr,CameronW;Perkowski,AndrewJ;Smith,Robert;Schoenen,FrankJ;Gold,BenS;Zhang,David;Nathan,CarlF;Dartois,Véronique;Aubé,Jeffrey
- 通讯作者:Aubé,Jeffrey
Rapid Emergence and Spread of Severe Acute Respiratory Syndrome Coronavirus 2 Gamma (P.1) Variant in Haiti.
- DOI:10.1093/cid/ciab736
- 发表时间:2022-06-10
- 期刊:
- 影响因子:0
- 作者:Tagliamonte MS;Mavian C;Zainabadi K;Cash MN;Lednicky JA;Magalis BR;Riva A;Deschamps MM;Liautaud B;Rouzier V;Fitzgerald DW;Pape JW;Morris JG;Salemi M
- 通讯作者:Salemi M
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
- DOI:10.1021/acsinfecdis.6b00172
- 发表时间:2017-02-10
- 期刊:
- 影响因子:5.3
- 作者:Totaro KA;Barthelme D;Simpson PT;Jiang X;Lin G;Nathan CF;Sauer RT;Sello JK
- 通讯作者:Sello JK
Nonredundant functions of Mycobacterium tuberculosis chaperones promote survival under stress.
- DOI:10.1111/mmi.14615
- 发表时间:2021-03
- 期刊:
- 影响因子:3.6
- 作者:Harnagel, Alexa;Quezada, Landys Lopez;Park, Sae Woong;Baranowski, Catherine;Kieser, Karen;Jiang, Xiuju;Roberts, Julia;Vaubourgeix, Julien;Yang, Amy;Nelson, Brock;Fay, Allison;Rubin, Eric;Ehrt, Sabine;Nathan, Carl;Lupoli, Tania J.
- 通讯作者:Lupoli, Tania J.
Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
- DOI:10.1186/s40168-017-0286-2
- 发表时间:2017-07-07
- 期刊:
- 影响因子:15.5
- 作者:Namasivayam S;Maiga M;Yuan W;Thovarai V;Costa DL;Mittereder LR;Wipperman MF;Glickman MS;Dzutsev A;Trinchieri G;Sher A
- 通讯作者:Sher A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Stephen Glickman其他文献
Michael Stephen Glickman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Stephen Glickman', 18)}}的其他基金
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
Rip1 控制结核分枝杆菌的应激抵抗力和毒力
- 批准号:
10547809 - 财政年份:2019
- 资助金额:
$ 63.29万 - 项目类别:
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
Rip1 控制结核分枝杆菌的应激抵抗力和毒力
- 批准号:
10338102 - 财政年份:2019
- 资助金额:
$ 63.29万 - 项目类别:
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
Rip1 控制结核分枝杆菌的应激抵抗力和毒力
- 批准号:
10084263 - 财政年份:2019
- 资助金额:
$ 63.29万 - 项目类别:
RP-4: Immunologic Predictors of BCG Immunotherapy for Bladder Cancer
RP-4:膀胱癌 BCG 免疫治疗的免疫预测因子
- 批准号:
10226974 - 财政年份:2018
- 资助金额:
$ 63.29万 - 项目类别:
RP-4: Immunologic Predictors of BCG Immunotherapy for Bladder Cancer
RP-4:膀胱癌 BCG 免疫治疗的免疫预测因子
- 批准号:
10453636 - 财政年份:2018
- 资助金额:
$ 63.29万 - 项目类别:
RP-4: Immunologic Predictors of BCG Immunotherapy for Bladder Cancer
RP-4:膀胱癌 BCG 免疫治疗的免疫预测因子
- 批准号:
9979823 - 财政年份:2018
- 资助金额:
$ 63.29万 - 项目类别:
Tri-Institutional TB Research Unit: Persistence and Latency
三机构结核病研究小组:持续性和潜伏期
- 批准号:
8691646 - 财政年份:2014
- 资助金额:
$ 63.29万 - 项目类别:
Tri-Institutional TB Research Unit: Persistence and Latency
三机构结核病研究单位:持续性和潜伏期
- 批准号:
9753887 - 财政年份:2014
- 资助金额:
$ 63.29万 - 项目类别:
Tri-Institutional TB Research Unit: Persistence and Latency
三机构结核病研究单位:持续性和潜伏期
- 批准号:
9081457 - 财政年份:2014
- 资助金额:
$ 63.29万 - 项目类别:
相似国自然基金
从CD4+、CD8+T细胞免疫活化分子及其上游调控因子表达探究健脾祛湿法治疗艾滋病免疫调节机制
- 批准号:81460716
- 批准年份:2014
- 资助金额:48.0 万元
- 项目类别:地区科学基金项目
HAART过程中HCV复制增强与肝细胞MAVS抗病毒通路的关系研究
- 批准号:81201286
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
IAS 2023, the 12th IAS Conference on HIV Science, Brisbane, Australia, and virtually, 23-26 July 2023
IAS 2023,第 12 届 IAS HIV 科学会议,澳大利亚布里斯班,虚拟会议,2023 年 7 月 23-26 日
- 批准号:
10696505 - 财政年份:2023
- 资助金额:
$ 63.29万 - 项目类别:
Multiscale Computational Microscopy of HIV-1
HIV-1 的多尺度计算显微镜
- 批准号:
10756808 - 财政年份:2023
- 资助金额:
$ 63.29万 - 项目类别:
Hepatotoxic mechanisms of anti-HIV- and anti-COVID-19 drugs and substance use disorders
抗 HIV 和抗 COVID-19 药物和物质使用障碍的肝毒性机制
- 批准号:
10684434 - 财政年份:2023
- 资助金额:
$ 63.29万 - 项目类别:
Development of an automated HIV self-testing assay
自动化 HIV 自检检测的开发
- 批准号:
10539345 - 财政年份:2022
- 资助金额:
$ 63.29万 - 项目类别:
National Biomedical Resource for Electron-Spin Resonance Spectroscopy (ACERT)
国家电子自旋共振光谱生物医学资源 (ACERT)
- 批准号:
10430665 - 财政年份:2022
- 资助金额:
$ 63.29万 - 项目类别: